# The Effects of Omalizumab (Anti-IgE) on the Late-phase Response to Nasal Allergen Challenge

> **NCT01003301** · PHASE2 · COMPLETED · sponsor: **Johns Hopkins University** · enrollment: 19 (actual)

## Conditions studied

- Cat Allergy

## Interventions

- **DRUG:** Omalizumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01003301
- **Lead sponsor:** Johns Hopkins University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-10
- **Primary completion:** 2012-12
- **Final completion:** 2013-09
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2014-04-07

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01003301

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01003301, "The Effects of Omalizumab (Anti-IgE) on the Late-phase Response to Nasal Allergen Challenge". Retrieved via AI Analytics 2026-06-19 from https://api.ai-analytics.org/clinical/NCT01003301. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*